tetano
Editor, Senior Moderator
Vaccine
. 2025 Aug 25:62:127597.
doi: 10.1016/j.vaccine.2025.127597. Online ahead of print. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)
Grace Li[SUP] 1 [/SUP], Natalie G Marchevsky[SUP] 2 [/SUP], Grace Macaulay[SUP] 2 [/SUP], Parvinder Aley[SUP] 2 [/SUP], Hannah Baughan[SUP] 2 [/SUP], Emma Plested[SUP] 2 [/SUP], Sagida Bibi[SUP] 2 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Saul N Faust[SUP] 3 [/SUP], Paul T Heath[SUP] 4 [/SUP], Jill Muller[SUP] 2 [/SUP], Hannah Robinson[SUP] 2 [/SUP], Marion Roderick[SUP] 5 [/SUP], Matthew Snape[SUP] 2 [/SUP], David Smith[SUP] 2 [/SUP], Rinn Song[SUP] 2 [/SUP], Xinxue Liu[SUP] 2 [/SUP], Teresa Lambe[SUP] 6 [/SUP], Andrew J Pollard[SUP] 7 [/SUP]; COV006 trial team
Collaborators, Affiliations
Background: Paediatric COVID-19 vaccination programmes were initiated in response to the coronavirus pandemic declared by the World Health Organisation (WHO) in 2020. Ten COVID-19 vaccines received WHO Emergency Use Listing, however, only five were approved for use in children. ChAdOx1 nCoV-19 (AZD1222) was approved in adults in a two-dose regimen. We previously reported interim findings of a phase 2 study of ChAdOx1 nCoV-19 in children with immunogenicity, comparable with adults. Final results after 12 month follow-up are reported.
Methods: Single-blind, randomised controlled trial across four UK centres, recruiting 261 children and adolescents (aged 6-17 years). Participants received either two doses of ChAdOx1 nCoV-19 or Bexsero vaccine (controls). The primary outcome was safety (adverse events for 28 days following vaccination and serious adverse events throughout), and secondary outcome was immunogenicity (measured by SARS-CoV-2 anti-spike enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunosorbent spot (ELISpot)).
Findings: Five serious adverse events and four adverse events of special interest were reported. None were related to study vaccinations, and there were no deaths. Geometric mean titres (GMTs) from an anti-spike (Wuhan) ELISA in participants aged 6-11 years were 1 EU/ml (95% CI 1-2) at baseline versus 796 EU (95% CI 161-3948, n =4) at D364. In participants aged 12-17 years, GMTs were 1 EU/ml (95% CI 1-2, n=3) at baseline versus 1432 EU/ml (95% CI 2337-6083; n=6) at D364 (2 dose regimen at 112-day interval), compared to 3 EU/ml (95% CI 0-62) at baseline versus 392 EU/ml (95% CI 24, 6493; n=3) at D364 (2 dose regimen at a 28-day interval).
Interpretation: A two-dose regimen of ChAdOx1 nCoV-19 was immunogenic and safe in the trial population. No vaccine-related serious adverse events were reported. Immune responses persisted to 12 months in participants who did not experience breakthrough infection, This trial was registered with ISRCTN, trial number 15638344.
Funding: The study was funded by the Department of Health and Social Care, through the National Institute for Health Research, and AstraZeneca.
Keywords: Paediatric vaccinology; SARS-CoV-2; Viral vectors.
. 2025 Aug 25:62:127597.
doi: 10.1016/j.vaccine.2025.127597. Online ahead of print. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine in children aged 6-17 years: Final results of a phase 2, single-blind, randomised controlled trial (COV006)
Grace Li[SUP] 1 [/SUP], Natalie G Marchevsky[SUP] 2 [/SUP], Grace Macaulay[SUP] 2 [/SUP], Parvinder Aley[SUP] 2 [/SUP], Hannah Baughan[SUP] 2 [/SUP], Emma Plested[SUP] 2 [/SUP], Sagida Bibi[SUP] 2 [/SUP], Federica Cappuccini[SUP] 2 [/SUP], Saul N Faust[SUP] 3 [/SUP], Paul T Heath[SUP] 4 [/SUP], Jill Muller[SUP] 2 [/SUP], Hannah Robinson[SUP] 2 [/SUP], Marion Roderick[SUP] 5 [/SUP], Matthew Snape[SUP] 2 [/SUP], David Smith[SUP] 2 [/SUP], Rinn Song[SUP] 2 [/SUP], Xinxue Liu[SUP] 2 [/SUP], Teresa Lambe[SUP] 6 [/SUP], Andrew J Pollard[SUP] 7 [/SUP]; COV006 trial team
Collaborators, Affiliations
- PMID: 40857840
- DOI: 10.1016/j.vaccine.2025.127597
Background: Paediatric COVID-19 vaccination programmes were initiated in response to the coronavirus pandemic declared by the World Health Organisation (WHO) in 2020. Ten COVID-19 vaccines received WHO Emergency Use Listing, however, only five were approved for use in children. ChAdOx1 nCoV-19 (AZD1222) was approved in adults in a two-dose regimen. We previously reported interim findings of a phase 2 study of ChAdOx1 nCoV-19 in children with immunogenicity, comparable with adults. Final results after 12 month follow-up are reported.
Methods: Single-blind, randomised controlled trial across four UK centres, recruiting 261 children and adolescents (aged 6-17 years). Participants received either two doses of ChAdOx1 nCoV-19 or Bexsero vaccine (controls). The primary outcome was safety (adverse events for 28 days following vaccination and serious adverse events throughout), and secondary outcome was immunogenicity (measured by SARS-CoV-2 anti-spike enzyme-linked immunosorbent assay (ELISA) and enzyme-linked immunosorbent spot (ELISpot)).
Findings: Five serious adverse events and four adverse events of special interest were reported. None were related to study vaccinations, and there were no deaths. Geometric mean titres (GMTs) from an anti-spike (Wuhan) ELISA in participants aged 6-11 years were 1 EU/ml (95% CI 1-2) at baseline versus 796 EU (95% CI 161-3948, n =4) at D364. In participants aged 12-17 years, GMTs were 1 EU/ml (95% CI 1-2, n=3) at baseline versus 1432 EU/ml (95% CI 2337-6083; n=6) at D364 (2 dose regimen at 112-day interval), compared to 3 EU/ml (95% CI 0-62) at baseline versus 392 EU/ml (95% CI 24, 6493; n=3) at D364 (2 dose regimen at a 28-day interval).
Interpretation: A two-dose regimen of ChAdOx1 nCoV-19 was immunogenic and safe in the trial population. No vaccine-related serious adverse events were reported. Immune responses persisted to 12 months in participants who did not experience breakthrough infection, This trial was registered with ISRCTN, trial number 15638344.
Funding: The study was funded by the Department of Health and Social Care, through the National Institute for Health Research, and AstraZeneca.
Keywords: Paediatric vaccinology; SARS-CoV-2; Viral vectors.